Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,690.00
  • Today's Change-24.00 / -1.40%
  • Shares traded91.36k
  • 1 Year change48.64%
  • Beta0.4091
Data delayed at least 20 minutes, as of Apr 28 2017 17:05 BST.
More ▼

Key statistics

On Friday, Dechra Pharmaceuticals PLC (DPH:LSE) closed at 1,690.00, -1.46% below its 52-week high of 1,715.00, set on Apr 28, 2017.
52-week range
Today
811.00Jun 24 20161,715.00Apr 28 2017
Markit short selling activity
Low
Med
High
Open1,713.00
High1,715.00
Low1,687.00
Bid1,610.00
Offer1,690.00
Previous close1,714.00
Average volume136.26k
Shares outstanding93.10m
Free float90.54m
P/E (TTM)111.61
Market cap1.57bn GBP
EPS (TTM)0.1514 GBP
Annual div (ADY)19.02 GBX
Annual div yield (ADY)1.13%
Div ex-dateMar 09 2017
Div pay-dateApr 07 2017
Data delayed at least 20 minutes, as of Apr 28 2017 17:05 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Dechra Pharmaceuticals PLC shares was Buy at 1,601.00 on 27 Feb 2017Read the full article

Board of Directors

1/7

Michael Redmond: Non-Executive Chairman

2/7

Ian Page: Chief Executive Officer

3/7

Tony Griffin: Managing Director, Dechra Veterinary Products EU

4/7

Ishbel Macpherson: Senior Independent Non-Executive Director

5/7

Julian Heslop: Non-Executive Director

6/7

Tony Rice: Non-Executive Director

7/7

Suzana Cross: General Counsel and Company Secretary

Preliminary Results for year ended 30 June 2014

Half Year Financial Report 2015

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.